1. Home
  2. AEMD vs HCWB Comparison

AEMD vs HCWB Comparison

Compare AEMD & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

N/A

Current Price

$5.47

Market Cap

3.9M

Sector

Health Care

ML Signal

N/A

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

N/A

Current Price

$1.03

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AEMD
HCWB
Founded
1984
2018
Country
United States
United States
Employees
9
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
3.6M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
AEMD
HCWB
Price
$5.47
$1.03
Analyst Decision
Hold
Analyst Count
2
0
Target Price
★ $13.25
N/A
AVG Volume (30 Days)
54.1K
★ 86.1K
Earning Date
11-16-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $4,099,750.00
Revenue This Year
N/A
$12,215.61
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.53
$0.86
52 Week High
$25.66
$23.94

Technical Indicators

Market Signals
Indicator
AEMD
HCWB
Relative Strength Index (RSI) 52.35 30.32
Support Level $4.86 $0.86
Resistance Level $6.69 $1.73
Average True Range (ATR) 0.39 0.08
MACD -0.03 0.03
Stochastic Oscillator 45.61 3.71

Price Performance

Historical Comparison
AEMD
HCWB

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: